Jeffrey Leiden, M.D., Ph.D.
Chairman, President and CEO
Dr. Leiden is the Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals. He received his B.A., M.D. and Ph.D. degrees from the University of Chicago. He is a physician and scientist who, for the last 30 years, has dedicated his career to improving the lives of people with serious diseases. Read more
He began his career in academia as a molecular biologist and practicing cardiologist. From 1987 to 2000, Dr. Leiden held several academic and hospital appointments, including the Frederick H. Rawson Professor of Medicine and Pathology and Chief of Cardiology at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School.
From 2000 to 2006, he served as President and Chief Operating Officer of Abbott Laboratories where he led Abbott’s global pharmaceuticals business. While at Abbott, Dr. Leiden led the development and launch of multiple breakthrough medicines, including Humira for rheumatoid arthritis and other autoimmune diseases and Kaletra for HIV infection.
From 2006 to 2011, he was a Managing Director of Clarus Ventures, a life sciences venture capital firm where he continued to develop new medicines, devices, and vaccines by investing in innovative biotech companies including TyRx, Catabasis, Lycera, and VBI.
Dr. Leiden has served as a member of Vertex’s board of directors since 2009 and as Chairman and CEO since 2012. Vertex invests in scientific innovation to discover and develop transformative medicines for people with Cystic Fibrosis (CF) and other serious diseases. Under his leadership, Vertex has developed Kalydeco and Orkambi, the first and only medicines to treat the underlying cause of CF.
In addition to his responsibilities at Vertex, Dr. Leiden is a director of both Quest Diagnostics and the Massachusetts Mutual Life Insurance Company, chair of the Scientific Advisory Board of the Brigham and Women’s Hospital and a member of the National Institutes of Health Advisory Council to the Director. Dr. Leiden also serves on the board of directors of the Massachusetts Competitive Partnership, the Board of Fellows of Harvard Medical School, the board of directors of the Museum of Fine Arts and the Boston Private Industry Council and as co-chair of Massachusetts Governor Charlie Baker’s STEM Advisory Council. He is a fellow of the American Academy of Arts and Sciences and an elected member of the National Academy of Medicine.
David Altshuler, M.D., Ph.D.
Executive Vice President, Global Research and Chief Scientific Officer
David Altshuler is Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals. Dr. Altshuler leads Vertex’s research efforts aimed at discovering new medicines for the treatment of CF and other serious diseases, overseeing the company’s five research sites in the United States, Canada and Europe. Read more
David was previously one of four founding members, Deputy Director and Chief Academic Officer at the Broad Institute of Harvard and MIT, a professor at Harvard and MIT, and a physician at Massachusetts General Hospital. He was a leader of the SNP Consortium, HapMap and 1,000 Genome Projects, and discovered over 100 gene variants associated with type 2 diabetes and other common diseases.
David serves as Chair of the Wellcome Trust Sanger Institute’s Scientific Advisory Board. A member of the National Academy of Medicine and the American Academy of Arts and Sciences, David was named a Champion of Change by the White House for his leadership in creating and leading the Global Alliance for Genomic and Health.
Stuart A. Arbuckle
Executive Vice President and Chief Commercial Officer
Mr. Arbuckle joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Commercial Officer, Mr. Arbuckle oversees Vertex’s global commercial team, which is responsible for the company’s reimbursement and access, sales, marketing, patient support, market research and other activities that support the approved use of Vertex’s cystic fibrosis medicines. Read more
Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at biopharmaceutical companies. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc. As Vice President and General Manager, Oncology Business Unit, he led sales, marketing, patient advocacy and access efforts for Amgen’s portfolio of cancer medicines. He was responsible for sales and marketing efforts for Aranesp®, Neulasta® and NEUPOGEN®, which accounted for more than $5 billion in sales in 2011, and led the successful launches of XGEVA® and Nplate®. Most recently, he served as Vice President and Regional General Manager where he led efforts to expand Amgen's presence in Japan, Asia, the Middle East and Africa.
Prior to these roles, Mr. Arbuckle spent 15 years at GlaxoSmithKline (GSK) plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He joined GSK after earning a degree in pharmacology and physiology from the University of Leeds in the United Kingdom.
Mr. Arbuckle currently serves as a member of Cerulean Pharma’s board of directors, as a national board member of the Cancer Support Community, an international non-profit dedicated to providing support, education and hope to people affected by cancer, and on the Health Section Governing Board for the Biotechnology Industry Organization. He is also co-chair of the BIO Standing Committee on Reimbursement.
Jeffrey A. Chodakewitz, M.D.
Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Dr. Chodakewitz joined Vertex in January 2014 and is the company’s Executive Vice President, Global Medicines Development and Affairs and Chief Medical Officer. He oversees clinical development, global regulatory affairs, medical affairs, drug safety and other related functions and is responsible for developing, advising and driving execution of Vertex’s clinical development programs. Read more
Prior to joining Vertex, Dr. Chodakewitz spent more than 20 years at Merck & Co., Inc., where he held a variety of roles including Vice President of Clinical Research – Infectious Diseases & Vaccines, Vice President of Clinical Pharmacology/Early Stage Development, Senior Vice President of Late Stage Development, and Senior Vice President of Global Scientific Strategy (Infectious Diseases, Respiratory/Immunology). Prior to his tenure at Merck, he served as the Director of the HIV Outpatient Clinic at the Veterans Administration Medical Center in West Haven, Connecticut and held various academic positions at Yale University and New York University Schools of Medicine.
Dr. Chodakewitz is a Diplomate of the National Board of Medical Examiners, the American Board of Internal Medicine (both Internal Medicine and Infectious Diseases), and is a member of the Infectious Disease Society of America (IDSA) and the American Society for Clinical Pharmacology & Therapeutics (ASCPT). He received a B.S. in Biochemistry from Yale University, cum laude, and an M.D. from the Yale University School of Medicine.
Michael J. Parini
Executive Vice President, Chief Legal and Administrative Officer
Mr. Parini joined Vertex in 2016 as the company’s Executive Vice President and Chief Legal Officer. He oversees Vertex’s global legal and compliance functions and also serves as a member of the company’s Executive Committee. Read more
Mr. Parini joined Vertex after more than a decade at Pfizer Inc. where he served in multiple leadership roles within the company's global legal team, including as Senior Vice President and Associate General Counsel. He was responsible for the strategic management of Pfizer's global litigation activities, including civil, intellectual property, government and employment litigation. He also served as Chief Counsel for multiple key business units within Pfizer, advising Pfizer's leadership team on business issues related to investment decisions, patent disputes, global pricing strategies and commercial operations activities, among other responsibilities.
Prior to Pfizer, Mr. Parini served as a health care attorney at Akin, Gump, Strauss, Hauer & Feld, L.L.P. in Washington, D.C., where he provided legal counsel on federal and state regulatory and policy issues.
Mr. Parini is a member of the New York and District of Columbia bars. He received a bachelor’s degree in American government from Georgetown University and a law degree from Georgetown University Law.
Amit K. Sachdev
Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
Mr. Sachdev joined Vertex in 2007. As Vertex’s Executive Vice President, Policy, Access and Value, Mr. Sachdev manages our global market access, health economics and outcomes research efforts for our approved and pipeline medicines. Read more
He also oversees our government affairs and public policy activities, as well as the company's patient advocacy programs. In 2010, he established our first international commercial operations.
Prior to Vertex, Mr. Sachdev served as Executive Vice President, Health, at the Biotechnology Industry Organization (BIO) and was Deputy Commissioner for Policy at the U.S. Food and Drug Administration (FDA) where he also held several other senior appointments beginning in 2002. Earlier in his career, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the U.S. House of Representatives and practiced law at the American Chemistry Council and subsequently at the law firm of Ropes & Gray.
Mr. Sachdev received a B.S from Carnegie Mellon University and a J.D. from Emory University School of Law.
Ian F. Smith
Executive Vice President, Chief Operating Officer and Chief Financial Officer
Ian Smith joined Vertex in November 2001. As Vertex’s Chief Operating Officer and Chief Financial Officer, Mr. Smith holds responsibility for core functions at Vertex, including Accounting, Finance, Strategic Sourcing, Corporate & Business Development, Corporate Strategy, Global Facilities and Operations, Global Information Systems, Corporate Real Estate Development, Pharmaceutical Operations and Investor Relations. Read more
Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001.
Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University, and Mr. Smith is a current member of the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute.
Mr. Smith is a member of the Board of Directors of Acorda Therapeutics, Infinity Pharmaceuticals and Ophthotech Corporation. He also serves as the Chairman of the Audit Committee for both Infinity Pharmaceuticals and Ophthotech.
Senior Vice President and General Manager, International Commercial Operations
Mr. Bedson joined Vertex in 2011 to lead Vertex’s global expansion and is the company’s Senior Vice President and General Manager, International Commercial Operations. Read more
He oversees global commercial activities outside of North America, which have included the establishment of the company’s first international headquarters in Switzerland as well as commercial offices and operations in Australia, the UK and Republic of Ireland, France, Germany, Benelux, Spain, Italy and other countries.
Mr. Bedson has three decades of pharmaceutical and biotech industry experience. Prior to Vertex, he was Vice President and General Manager of Europe and Australia at Gilead, where he led the company’s country operations across nine affiliate markets over a three-year period. Prior to that, Mr. Bedson spent 10 years at Amgen, including four at the company’s U.S. headquarters, in a variety of leadership roles.
Mr. Bedson has a B.Sc. in Biology from University College London and an M.B.A. from Ashridge Management College in the UK.
Patricia Hurter, Ph.D.
Senior Vice President, CMC and Preclinical Development
Dr. Hurter joined Vertex in 2004 as Head of Formulation Development, became the Vice President of Pharmaceutical Development in 2006, and is currently the Senior Vice President of CMC and Preclinical Development. Read more
The scope of her responsibilities include Pharmaceutical Development (development of chemical processes for drug substance manufacture as well as drug product formulation and process development, and associated characterization methods for activities from the discovery phase through to validation for commercial manufacturing), DMPK (preclinical drug metabolism and pharmacokinetics) and drug safety evaluation.
Prior to joining Vertex, Dr. Hurter was Director of Formulation Development at Merck from 2000 to 2004. Before joining the pharmaceutical industry, Dr. Hurter worked in the paper industry for 8 years where she studied the microstructure of paper and its effects on end use performance.
Dr. Hurter has a Ph.D. in Chemical Engineering from M.I.T., an M.S. in Mechanical Engineering from West Virginia University and a B.Sc. in Chemical Engineering from the University of Natal, Durban, South Africa.
Vice President, Corporate Communications
Ms. Kalmar is the Vice President of Corporate Communications. In this role, she is responsible for corporate and product communications, employee communications and engagement, corporate branding and design, media relations and executive communications. Ms. Kalmar also oversees Vertex’s Thomas M. Menino Learning Lab – a collaboration with the Boston Public School system to enhance Science, Technology, Engineering and Math (STEM) education through hands-on learning. Read more
Since joining Vertex in September 2010, Ms. Kalmar has held several senior-level positions, serving as Director of Product Communications for the back-to-back approvals and launches of the company’s first two marketed medicines and Senior Director of Internal/Executive Communications, before being named Vice President of Corporate Communications in 2014.
Ms. Kalmar has more than fifteen years of biotech and pharmaceutical experience. Prior to Vertex, she held various communications roles at Genentech during a period of significant growth for the company. In her seven years there, she supported various external and internal communications, patient advocacy and community relations. During her tenure, she led public relations (PR) activities for Genentech’s top three branded biopharmaceuticals – Avastin, Lucentis and Rituxan – including the launch of Lucentis for wet age-related macular degeneration. Ms. Kalmar has experience in issues and crisis management as well as mergers and acquisitions. She began her career with a PR agency where she managed communications programs for biotech, pharmaceutical and medical device clients.
Ms. Kalmar has a B.S. in Journalism from California Polytechnic State University-San Luis Obispo.
Vice President, Investor Relations
Mr. Partridge joined Vertex in 1997 and has served in a number of roles leading the company’s product communications, corporate branding and communications, and investor relations efforts. He is currently the company’s Vice President of Investor Relations and is responsible for Vertex’s global investor relations program. Read more
Prior to Vertex, Mr. Partridge spent four years at Decision Resources, a privately owned consulting and advisory firm for the healthcare, pharmaceutical and financial industries. At Decision Resources, he analyzed the impact of new health care technologies, the global market opportunity for new treatments in key disease areas, and corporate strategy for pharmaceutical and biotech clients. His work on a report projecting the rapid development of the HIV market led him to his role at Vertex.
Mr. Partridge has a B.A. in English from the University of Massachusetts Amherst.